TYRX, Inc. introduces AIGISRx® ST, its antibacterial product for the surgical repair of damaged or ruptured soft tissue. TYRX had previously received 510(k) clearance to market a product for hernia repair and other abdominal soft tissue deficiencies. The new clearance adds the use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue.

According to the company, the product delivers:

• Antimicrobial agents, rifampin and minocycline that have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
• A resorbable polymer containing the antimicrobial agents rifampin and minocycline to help provide protection from microbial colonization.

For more information, visit www.TYRX.com